BIIB142

BIIB142 is a small molecule **targeted protein degrader** of the enzyme **interleukin-1 receptor-associated kinase 4 (IRAK4)**, developed using targeted protein degradation technology. It is being advanced for the treatment of autoimmune diseases through rapid and selective degradation of IRAK4, a key signaling protein in innate immunity and inflammation. BIIB142 represents the first IRAK4 degrader to enter clinical development for autoimmune conditions, marking a novel approach distinct from traditional kinase inhibitors. The drug is a result of a collaboration between Biogen and C4 Therapeutics, with Biogen handling its clinical development and future commercialization[1][2][3][9].